FDA Panel Approves Innovative Blood Test for Cancer Detection
WHO:
CNN - Dr. Vershalee Shukla runs a cancer screening program for firefighters in Arizona.
AP News - The FDA panel endorsed a blood test developed by Grail.
WHAT:
Investor's Business Daily - The Galleri test promises comprehensive early-stage screening for more than 50 types of cancer.
Inc - The Galleri test is priced at $1,000, which is consistent with previous reports but emphasizes its role in early-stage cancer detection.
Investor's Business Daily - The FDA panel's endorsement marks a significant step for the Galleri test, which is the first of its kind to use a blood sample to detect multiple forms of cancer.
ABC News US - The blood test, called Galleri, is designed to detect over 50 types of cancer through a single blood draw.
CNN - The cost of the Galleri test is approximately $1,000.
CNN - Dr. Vershalee Shukla's team found 15 cases of cancer after convincing firefighters to return for regular screenings, following a period where they relied on negative Galleri results.
CNN - Dr. Shukla's team has run close to 10,000 liquid biopsies over the past five years, catching fewer than a dozen cases of cancer.
AP News - The blood test is designed to detect multiple types of cancer in healthy individuals.
ABC News US - This blood test is facing its first major regulatory review by the FDA.
WHERE:
AP News - The review is taking place in the United States.
WHEN:
ABC News Tech - The FDA panel's decision is part of the ongoing regulatory review process for the Galleri test, which is expected to conclude by the end of 2026.
ABC News US - The FDA is expected to make a decision on the blood test by the end of 2026.
WHY:
Inc - The test aims to address the lack of recommended screening tests for many cancers, which are typically diagnosed later when treatment is more challenging.
CNN - Dr. Shukla emphasized that a negative Galleri result does not guarantee that an individual is cancer-free, highlighting the importance of routine screenings.
ABC News US - The test aims to improve early cancer detection, which is crucial for effective treatment.
HOW:
CNN - Dr. Shukla reported that after drawing blood from 500 firefighters, every single result came back negative, leading to a false sense of security among the firefighters regarding their health.
AP News - The blood test works by analyzing genetic material from cancer cells that may be present in the bloodstream.
(UPDATED September 24, 2026 20:58 UTC)
The Galleri test is making headlines for its promise of comprehensive early-stage screening for over 50 types of cancer. Priced at $1,000, this test emphasizes its crucial role in early detection, addressing the significant gap in recommended screening for many cancers that are often diagnosed at more advanced stages. By focusing on early-stage detection, the Galleri test aims to improve treatment outcomes for patients facing these challenging diagnoses.
--
(UPDATED September 24, 2026 09:02 UTC)
The FDA panel has endorsed the Galleri test, marking a significant advancement as it is the first test of its kind to use a blood sample to detect multiple forms of cancer. This decision is part of the ongoing regulatory review process for the Galleri test, which is expected to conclude by the end of 2026. The endorsement represents a hopeful step forward in cancer detection technology.
--
(UPDATED September 24, 2026 07:09 UTC)
A new blood test called Galleri is making headlines for its ability to detect over 50 types of cancer with just a single draw, but it comes at a cost of about $1,000. Dr. Vershalee Shukla's team discovered 15 cases of cancer among firefighters who returned for regular screenings after initially relying on negative Galleri results. She stressed that a negative result from the Galleri test does not guarantee that someone is cancer-free, underscoring the need for ongoing routine screenings.
--
(UPDATED September 24, 2026 02:10 UTC)
Dr. Vershalee Shukla, who runs a cancer screening program for firefighters in Arizona, has reported that her team has conducted nearly 10,000 liquid biopsies over the past five years, identifying fewer than a dozen cases of cancer. Recently, after testing blood from 500 firefighters, every single result returned negative, which has created a false sense of security about their health. This situation highlights the complexities and challenges of cancer screening in high-risk professions.
--
(UPDATED September 24, 2026 01:25 UTC)
A panel from the FDA has endorsed a new blood test developed by Grail, which is designed to detect multiple types of cancer in healthy individuals. This test is currently undergoing its first major regulatory review in the United States, with a decision expected by the end of 2026. By analyzing genetic material from cancer cells that may be present in the bloodstream, the test aims to improve early cancer detection, a crucial factor for effective treatment.